🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,180 results for “Takeda Pharmaceuticals International AG” Clear

  1. Amlodipine

    Takeda Pharmaceuticals International AG

    Hypertension

    phase 3 small molecule terminated

    1 trial

  2. Anagrelide Hydrochloride

    Takeda Pharmaceuticals International AG

    Essential Thrombocythemia (ET)

    phase 3 small molecule completed

    1 trial

  3. Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg

    Takeda Pharmaceuticals International AG

    Major Depressive Disorder

    phase 3 small molecule completed

    3 trials

  4. Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)

    Takeda Pharmaceuticals International AG

    Hemophilia A

    phase 3 mab terminated

    1 trial

  5. Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)

    Takeda Pharmaceuticals International AG

    Hemophilia A

    phase 3 small molecule completed

    1 trial

  6. Azacitidine

    Takeda Pharmaceuticals International AG

    Myelodysplastic Syndrome

    phase 3 small molecule completed

    1 trial

  7. Azilsartan

    Takeda Pharmaceuticals International AG

    Pediatric Hypertension

    phase 3 small molecule completed

    2 trials

  8. Azilsartan Medoxomil

    Takeda Pharmaceuticals International AG

    Hypertension

    phase 3 small molecule completed

    7 trials

  9. Azilsartan Medoxomil and amlodipine

    Takeda Pharmaceuticals International AG

    Hypertension

    phase 3 small molecule completed

    1 trial

  10. Azilsartan medoxomil and chlorthalidone

    Takeda Pharmaceuticals International AG

    Hypertension

    phase 3 small molecule completed

    2 trials

  11. Azilsartan medoxomil and chlorthalidone

    Takeda Pharmaceuticals International AG

    Essential Hypertension

    phase 3 small molecule completed

    4 trials

  12. Azilsartan medoxomil and chlorthalidone

    Takeda Pharmaceuticals International AG

    Safety

    phase 3 small molecule completed

    1 trial

  13. Azilsartan medoxomil and olmesartan

    Takeda Pharmaceuticals International AG

    Hypertension

    phase 3 small molecule completed

    1 trial

  14. Azilsartan medoxomil with or without add-on chlorthalidone

    Takeda Pharmaceuticals International AG

    Hypertension

    phase 3 small molecule completed

    1 trial

  15. Azilsartan medoxomil/placebo

    Takeda Pharmaceuticals International AG

    Essential Hypertension

    phase 3 small molecule completed

    1 trial

  16. BAX 326

    Takeda Pharmaceuticals International AG

    Hemophilia B

    phase 3 mab completed

    1 trial

  17. BAX 326 (Recombinant factor IX)

    Takeda Pharmaceuticals International AG

    Hemophilia B

    phase 3 mab completed

    1 trial

  18. BAX326

    Takeda Pharmaceuticals International AG

    Hemophilia B

    phase 3 mab completed

    1 trial

  19. BAX855

    Takeda Pharmaceuticals International AG

    Hemophilia A

    phase 3 mab completed

    1 trial

  20. Brentuximab Vedotin

    Takeda Pharmaceuticals International AG

    Primary Cutaneous Anaplastic Large Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  21. Brentuximab vedotin

    Takeda Pharmaceuticals International AG

    Diffuse Large B-cell-lymphoma

    phase 3 small molecule active

    1 trial

  22. Brigatinib

    Takeda Pharmaceuticals International AG

    ALK+ Advanced NSCLC

    phase 3 small molecule completed

    1 trial

  23. Budesonide oral suspension

    Takeda Pharmaceuticals International AG

    Eosinophilic Esophagitis (EoE)

    phase 3 small molecule terminated

    1 trial

  24. C1 esterase inhibitor [human] (C1INH-nf)

    Takeda Pharmaceuticals International AG

    Hereditary Angioedema

    phase 3 mab completed

    5 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources